Vertex is extending its lead in the cystic fibrosis space and setting a premium price for its next-generation triple-combination product Alyftrek (vanzacaftor/tezacaftor/deutivacaftor), which it intends to gradually replace its blockbuster Trikafta (elexacaftor/tezacaftor/ivacaftor). The Boston-based company set a wholesale acquisition cost (WAC) of $370,269 a year for Alyftrek, roughly a 7% premium over Trikafta’s US pricing.
Vertex New CF Combo Addresses More Patients, With Daily Dosing
Vertex hopes to convert CF patients to new combo Alyftrek from Trikafta with once-daily dosing. Approved on 20 December, the new triplet has longer patent protection and 7% higher US pricing.
More from New Products
• By
The company is planning to launch oxylanthanum carbonate for chronic kidney disease patients on dialysis with hyperphosphatemia.
• By
After a long wait for patients, Vykat has become the first drug approved for Prader-Willi syndrome symptoms, opening the market up for Soleno and future challengers.
• By
The US FDA approved Blujepa for the treatment of uncomplicated urinary tract infections, marking the first new mechanism of action for the infection in more than 30 years.
• By
Novartis US president Victor Bultó talked to Scrip about the company’s efforts to reach patients with rare kidney diseases who are candidates for Fabhalta.
More from Therapy Areas
• By
After a long wait for patients, Vykat has become the first drug approved for Prader-Willi syndrome symptoms, opening the market up for Soleno and future challengers.
• By
With its exon 53-skipping candidate already showing promise in 24-week data, Wave now has 48-week data showing improvements in muscle health and functional outcomes.
• By
J&J is confident that its bispecific antibody/kinase inhibitor combo’s overall survival win over AstraZeneca’s single-agent pill will shift the standard of care.